SecBot SecBot
8-K ·Filed Sep 22, 2026

ISPR

Ispire Technology Inc.
BULLISH
Impact 5/10
Horizonmonths Processed1mo ago SEC0001213900-26-102333
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

Monitor for PMTA decisions and commercial licensing agreements for IKE age-gating technology, as these could unlock the flavored vape market. Watch for production ramp at the new 136,000 sq ft Malaysia facility and any ODM partnership announcements with major tobacco companies.

DirectionBullish
Confidencemedium
Horizonmonths
Latest settled — T+20d
ISPR ▲ +0.38% at T+20d
LONG call ✓ call won +0.38% · α vs SPY -0.31% · entry $1.33 → $1.33
Next anchor: T+60d in 7w
Latest observation: T+22 -0.98% FF3 residual α
Entry = T+0 close
Sep 22, 2026
via day close
T+1d
-2.64%
call -2.64% · α -2.56%
$1.29
settled 5w ago
T+5d
-3.40%
call -3.40% · α -2.72%
$1.28
settled 28d ago
T+20d
+0.38%
call +0.38% · α -0.31%
$1.33
settled 7d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

Ispire Technology Inc. published an updated investor presentation on September 22, 2026, highlighting Q4 FY2026 revenue growth of 33% YoY to $26.7M, TTM revenue of $96M, and a strategic shift to Malaysia manufacturing with exclusive nicotine licenses. The presentation emphasizes a potential near-term path to profitability, FDA age-gating pathways for flavored vapes, and multiple growth vectors including nicotine pouches and G-Mesh technology.

Key Facts

  • Q4 FY2026 revenue of $26.7M, up 33% YoY from $20.1M in Q4 FY2025
  • TTM revenue of $96M as of June 30, 2026
  • Operating expenses reduced 28.6% YoY
  • Improvement in operating cash flow YoY
  • Credit loss reduced 5.8% YoY
  • Holds exclusive nicotine manufacturing license for e-cigarettes in Malaysia
  • Holds one of two nicotine pouch manufacturing licenses in Malaysia
  • 136,000 sq ft manufacturing facility with capacity of 61M devices or 107M pods per month
  • IKE age-gating technology has regulatory traction with FDA and UK recognition
  • FDA draft guidance in April 2026 provides pathway for flavored ENDS via Device Access Restrictions

Financial Impact

Q4 FY2026 revenue grew 33% YoY to $26.7M; TTM revenue $96M; operating expenses down 28.6% YoY

revenueoperating expensesoperating cash flowcredit loss

Risk Factors

  • FDA PMTA approvals are uncertain and subject to regulatory risk
  • Shift to Malaysia manufacturing may face operational execution risks
  • IKE age-gating technology commercial adoption is unproven at scale
  • Company has not yet achieved profitability or positive cash flow

Investment Themes

Consumer & Retail

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-102333
Document: ea0306279-8k_ispire.htm0001213900-26-102333
Document: 0001213900-26-102333-index-headers.html0001213900-26-102333
Document: 0001213900-26-102333-index.html0001213900-26-102333
Document: 0001213900-26-102333.txt0001213900-26-102333
3 reports for ISPR
Performance horizon
Filters
Rows
Reports for ISPR — sortable, filterable
TypeNow
Sep 22, 2026
4w ago
8-K
BULLISH ★ 5/10
$1.33 $1.33▲ +0.38%▼ −0.31%$1.36 (+2.64%)
Sep 17, 2026
5w ago
8-K
MIXED ★ 6/10
$1.30 $1.44▲ +10.77%▲ +9.56%$1.36 (+4.62%)
Aug 17, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$1.57 $1.44▼ −8.28%▼ −6.30%$1.36 (−13.38%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 22, 2026